Since founding Carterra (formerly Wasatch Microfluidics) in 2005, Mr. Eckman has been instrumental in securing funding, attracting key employees and advisors, developing strategic partnerships, designing Carterra’s proprietary flexible manufacturing process, securing international distributorships, and building out the sales channels for current products. Mr. Eckman previously worked with the Lassonde New Venture Development Center, moving university technologies into the marketplace. Mr. Eckman graduated summa cum laude in Business Administration and Asian Studies from the University of Utah. At graduation, he was awarded the Outstanding Scholar in Business Administration and the Honors Baccalaureate Award. Mr. Eckman also received a M.S. in Mechanical Engineering (microfluidics focus) from the University of Utah.
Dr Abdiche is Chief Scientific Officer at Carterra, where she has helped to develop and commercialize a high throughput Array SPR instrument for antibody screening. Prior to joining Carterra, she had a twelve-year career at Pfizer-Rinat leading a bioanalytical team that applied label-free biosensors to the discovery of therapeutic antibodies. As a Research Fellow she served on Rinat’s leadership team and the governing committee for Pfizer’s Postdoctoral Program. Dr Abdiche graduated from Oxford University with a PhD in Biological Chemistry and a Master’s degree in Chemistry and completed postdoctoral research at the University of Utah where she focused on optimizing biosensor methods for characterizing small molecule interactions. She helped to establish carbonic anhydrase as a model system within the biosensor community and has co-authored over 35 peer-reviewed papers on the application of biosensors in drug discovery. She has over 12 issued patents in the antibody space and is co-inventor of several drugs that entered the clinic, including PF-06801591, a PD-1 inhibitor that completed PhI clinical trials for cancer immunotherapy. Notably, she is co-inventor of Ajoyv (fremanezumab) a humanized monoclonal antibody that is the first and only anti-CGRP treatment for the prevention of migraine with quarterly and monthly dosing options, approved for market use in September 2018.
Tim Germann leads our customer-facing functions—sales, service, and support. He is a sales and operational leader who has built or rebuilt commercial teams and revenue streams in the life sciences and healthcare for more than 25 years. His successful tenures include Molecular Devices (now Danaher), Affymetrix (now Thermo Fisher), Metabolon, and Hill-Rom. At Hill-Rom, Tim led the global commercial operation for the healthcare IT division which drove more than $300 million of increased valuation in the business during a five-year turnaround. Most recently, Mr. Germann was COO and Chief Commercial Officer at RF Technologies where he led successful revitalization and growth initiatives across sales, marketing, service, finance, and manufacturing. Tim graduated from the Marriott School of Management at Brigham Young University and established a successful management consulting practice prior to joining Carterra.
With over 20 years of bio-industry experience, gained in both scientific and commercial roles, Julian brings a wealth of expertise in sales development and expansion for instrumentation and contract research services. Julian has strong international experience, having held senior scientific, commercial and management positions at leading biotech, instrumentation and service providers, including: Xenova Discovery Ltd (UK); Biacore AB (Sweden, now part of GE Healthcare); Amphora Discovery Corp. (USA); and multiple technology start-ups (USA & Europe) through his consultancy company. Julian earned a BSc in Clinical Biochemistry and his Master’s degree in Analytical Chemistry from the University of Greenwich, London, UK.